Background--Optimal thromboprophylaxis after cardiac surgery is uncertain. This systematic review aimed to define the incidence and risk factors for deep vein thrombosis (DVT), fatal and nonfatal pulmonary embolism (PE), and assess whether venous thromboembolism (VTE) prophylaxis was effective in reducing VTE without complications after cardiac surgery.
H ospitalization is a major risk factor for venous thromboembolism (VTE). According to the latest Centers for Disease Control and Prevention (CDC) analysis, approximately 547 596 hospitalizations were complicated by VTE each year among those age ≥18 years in the United States. 1 Deep vein thrombosis (DVT) occurred in 348 558 hospitalizations, pulmonary embolism (PE) occurred in 277 549 hospitalizations, and concomitant DVT and PE occurred in 78 511 hospitalizations each year. The total cost of VTE per person including loss of productivity and well-being was estimated to be over A$1 470 000 in the year 2008, and it was estimated that the total cost of VTE for Australia in 2008 was A3.9 billion, more than the costs of all other diseases including cancers. 2 The practice of VTE prophylaxis after cardiac surgery is controversial. According to the European Association for Cardiothoracic Surgery (EACTS) guidelines, prophylactic anticoagulation for VTE should be commenced from the first postoperative day. 3 However, an increased risk of bleeding and cardiac tamponade resulting from pharmacological thromboprophylaxis remains a major concern for patients who have undergone cardiac surgery. 4 Indeed, the latest American College of Chest Physicians evidence-based clinical practice guidelines on antithrombotic therapy and prevention of thrombosis have also stressed that patients after cardiac surgery are at high risk of major bleeding complications with only moderate risk for VTE (Grade-2C), and suggested that 6 Therefore, patients after cardiac surgery are not necessarily protected from VTE from day 1 postoperatively, despite their tendency for bleeding during the intraoperative and immediate postoperative period. Whether the benefits of VTE prophylaxis would outweigh its possible harms in patients after cardiac surgery remains contentious.
In this systematic review, we aimed to define the incidence of DVT, fatal and nonfatal PE, risk factors for VTE, and also to assess whether VTE prophylaxis was indeed effective in reducing VTE without increasing risk of complications after cardiac surgery.
Methods Data Sources and Study Selection
Two reviewers searched the Cochrane controlled trial register (2014, issue 4) and the EMBASE (January 1988 to December 12, 2014) and MEDLINE databases (1966 to December 12, 2014) independently. During the electronic database search, the following exploded Medical Subject Heading (MeSH) terms were used: "heart surgery" or "cardiac surgery" or "coronary artery bypass" or "valve surgery" or "valvular surgery" AND "venous thromboembolism" or "pulmonary embolism" or "deep vein thrombosis". The search included all forms of publications, including case series, cohort or case control studies, clinical trials, letters, editorials, reviews, meta-analysis, or randomized, controlled trials (RCTs) without any age or language restrictions. Animal studies, studies without involving cardiac surgery, or isolated case reports were excluded from this review. The reference lists of related editorials, reviews, and original articles identified were searched for relevant studies. Finally, the websites of the International Network of Agencies of Health Technology Assessment in Health Care were searched to ensure all suitable trials were included. Two reviewers independently examined all identified studies to confirm they fulfilled the inclusion criteria and VTE outcomes were reported. For RCTs, the quality of the trial, such as allocation concealment, randomization method, and blinding of treatment and assessment of outcome, was assessed. The grading of allocation was based on the Cochrane approach, that is, adequate, inadequate, or uncertain. When the reported methodology and results of the included trials were unclear, the corresponding authors of the trials were contacted to clarify the data (n=2, but 1 did not respond to our study inquiries). Any disagreements between the 2 independent reviewers were resolved by consensus.
Data Reporting and Statistical Analysis
VTE was the primary outcome of this review, and, whenever possible, we reported the incidence of symptomatic and asymptomatic VTE separately. In trying to identify the risk factors for VTE and complications after the use of VTE prophylaxis, only risk factors that were significant in the multivariate analyses were reported in this review. We also assessed whether the incidence of DVT was different between the leg with and without the great saphenous vein harvested for coronary artery bypass grafting (CABG) surgery.
The other outcomes assessed included the risk factors for bleeding complications or cardiac tamponade. In trying to identify whether VTE prophylaxis, in general, would be effective in reducing VTE after cardiac surgery, all interventions aimed to VTE were analyzed together against no comparative VTE prophylaxis. Outcomes were reported as relative risk (RR) with 95% confidence interval (CI), using a random-effects model (with the Mantel-Haenszel method, which estimates the amount of between-study variation by comparing each study's result with a Mantel-Haenszel fixedeffect meta-analysis result). The presence of heterogeneity between trials was assessed by the chi-square statistics and the extent of inconsistency was assessed using I 2 statistics.
14 An I 2 >40% was considered as significant heterogeneity in this study, and when heterogeneity was present, the data were further examined to explore for reasons for the heterogeneity by metaregression. 
Sensitivity Analysis
In assessing the incidence of VTE, we did a sensitivity analysis by restricting the analysis to higher-quality studies (RCTs and prospective cohort studies). We also assessed whether the incidence of VTE was related to the sample size of the studies and how recent the study was conducted. In assessing effectiveness of VTE prophylaxis, we did a sensitivity analysis by restricting our analysis to studies that had adequate allocation concealment. In assessing whether the leg with the great saphenous vein harvested was associated with a higher risk of DVT, we restricted our analysis to studies that utilized routine ultrasound scans on both legs regardless of whether the patients had symptoms of DVT.
Results

Study Characteristics
Of the 6636 studies identified in the literatures search, a total of 68 studies provided data on VTE outcomes or complications related to VTE prophylaxis after cardiac surgery ( Figure 1 ). The majority of the studies were observational studies (n=49), 16 studies were RCTs, and 3 were metaanalyses (Tables 1 and 2) . Of the 16 RCTs identified,* only 9 studies had allocation concealment and 6 used some form of blinding (Table 1) . Seven RCTs assessed 1 method of VTE prophylaxis against a placebo or control group, and 5 studies compared 1 pharmacological agent against another (eg, 3 studies on warfarin vs. aspirin, 2 studies on unfractionated heparin [UFH] vs. low-molecular-weight heparin [LMWH] or hirudin). Six RCTs compared interventions primarily not aiming at reducing VTE, but VTE data were reported (eg, activated factor VIIa, off-pump CABG vs. on-pump CABG, placebo vs. cyclooxygenase 2 inhibitors, and different types of autograft/prosthesis or cell saver devices) ( Table 1) . The 3 meta-analyses identified were related to use of factor VIIa or tranexamic acid for adult cardiac surgery and warfarin versus antiplatelet agents after Fontan surgery for congenital heart diseases. 62, 63, 74 Of the 49 observational studies included in this study, only 9 (18%) were prospective studies and 13 reported risk factors for VTE events or complications from VTE prophylaxis after adjusting for known risk factors for VTE or complications with a multivariate analysis, respectively (Table 2) .
VTE Events After Cardiac Surgery With Prophylaxis Versus Control/Placebo
Pooling all forms of VTE prophylaxis after cardiac surgery together, VTE prophylaxis was associated with a reduced risk of PE (RR, 0.45; 95% CI, 0. Using VTE as an outcome measure, the funnel plot did not suggest presence of a significant publication bias ( Figure 6 ).
VTE Events After 2 Different VTE Pharmacological Prophylaxis Agents
Only a small number of patients (n=276) had been enrolled in 3 RCTs comparing warfarin against high-dose aspirin (>300 mg/day for adults, 5 mg/kg per day for children), and the risk of VTE was not different (RR, 0.97; 95% CI, 0.50-1.89; P=0.94; I 2 =0%). One meta-analysis comparing aspirin with warfarin after Fontan surgery also did not show a significant difference in symptomatic VTE. 63 Similarly, only a very small number of patients (n=59) had been enrolled in a direct comparison between UFH and LMWH or hirudin, and the risk of VTE was also not different between the 2 groups Not reported No multivariate analysis on VTE, bleeding requiring reoperation in 24 patients (3.6%), but uncertain whether bleeding was related to VTE prophylaxis as the latter information was not described.
Retrospective, no blinding bd indicates twice a day; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CTPA, computed tomographic pulmonary angiogram; DVT, deep vein thrombosis; GCS, graduate compression stockings; HIT, heparin-induced thrombocytopenia; HR, hazard ratio; ICD, International Classification of Diseases; IV, intravenous; INR, international normalized ratio; IPPV, invasive mechanical ventilation; LMWH, low-molecular-weight heparin; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; OR, odds ratio; PE, pulmonary embolism; RCT, randomized, controlled trial; SC, subcutaneous; SCPC, superior cavopulmonary connection; tds, three times a day; TEE, transesophageal echocardiography; UFH, unfractionated heparin; USS, ultrasound scan; VTE, venous thromboembolism.
(RR, 3.0; 95% CI, 0.14-66; P=0.49). There were no RCTs directly comparing UFH or LMWH against aspirin alone for VTE prophylaxis after cardiac surgery.
Incidences and Risk Factors for Symptomatic and Asymptomatic VTE
The median incidence (interquartile range; IQR) of asymptomatic DVT and PE reported in the included studies were 14.8% (10.8-40.4) and 1.9% (0.4-25), respectively. The median incidence (IQR) of symptomatic DVT, PE, and fatal PE were 3.2% (0.6-8.1), 0.6% (0.3-2.9), and 0.3% (0.08-1.7), respectively. After restricting our analysis to only prospective cohort studies or RCTs, the median incidence of symptomatic PE (0.7%; IQR, 0.1-1.7) and fatal PE (0.4%; IQR, 0.3-1.4) were similar to when all studies were considered. The incidence of symptomatic PE and fatal PE were not associated with the sample size of the included studies (P=0.606 and 0.142, respectively) or how recent the study was conducted (P=0.207 and 0.802, respectively). Incidence of VTE and modality used to diagnose DVT and PE for each RCT as well as observational study are described in Table 2 . For prospective studies, all patients with clinical signs of DVT were expected to have an ultrasound scan (USS) as part of the studies, but the percentage of patients who had USS when clinical signs of DVT were present in the retrospective studies was not available. We identified 2 large postmortem studies, and, in these 2 studies, fatal PE accounted for 11% to 20% of the unexplained deaths after cardiac surgery. 57, 58 Diagnosis of PE was suspected or diagnosed clinically by a CT pulmonary angiogram before death only in 33% to 42% of the patients. 57, 58 Many patients who died from fatal PE were misdiagnosed clinically as having acute heart failure, acute myocardial infarction, pneumonia, or sudden cardiac death. 57 Fatal PE was reported within 24 hours of cardiac surgery in at least 1 observational study. 26 The risk factors for VTE after cardiac surgery that remained significant after adjustment by a multivariate analysis are summarized in Table 3 . Previous history of VTE, increasing age, obesity, left or right ventricular failure, prolonged bed rest/mechanical ventilation/use of a central venous catheter, and omission of all forms of anticoagulation or -platelet agents were the most consistent risk factors for VTE after cardiac surgery. Results of 2 meta-analyses on use of activated factor VIIa or tranexamic acid could not confirm these drugs as a significant risk factor for VTE after cardiac surgery. 62, 74 There was a suggestion that the leg with the great saphenous vein harvested could have a higher risk of DVT compared to the contralateral leg (RR, 1.48; 95% CI, 0.96-2.26; P=0.07; I 2 =71%), but this result did not reach statistical significance and had substantial heterogeneity ( Figure 7 ). Restricting the analysis to studies that used routine USS for both legs 20 Figure 8 ), with large sample size studies more likely to show an increased risk of DVT in the leg with the great saphenous vein harvested than smaller studies.
Incidences and Risk Factors for Complications From VTE Prophylaxis
Eight studies reported incidence of bleeding after cardiac surgery, 17, 19, 25, 53, 54, 78, 84 but only 1 study reported risk factors for bleeding after multivariate analysis, with concurrent use of aspirin with systemic anticoagulation as the only significant risk factor in causing bleeding after valvular surgery, with some of these bleeding patients with an international normalized ratio (INR) >5.
53
Although pericardial effusion was common after cardiac surgery (up to 84%), 76 using different doses of enoxaparin (20 vs. 40 mg/day) for VTE prophylaxis after proximal aortic surgery did not affect the incidence of pericardial effusion (19% vs. 21%, respectively) nor the risk of cardiac tamponade requiring surgical interventions. 75 Similarly, initiation of systemic anticoagulation for confirmed VTE also did not increase the risk of pericardial effusion in patients who took aspirin after CABG surgery. 27 Similar to bleeding after cardiac surgery, therapeutic systemic anticoagulation (INR >2.5) was the only reported risk factor for cardiac tamponade after valvular surgery in another observational study not included in this review. 85 No multivariate analysis on risk factors for cardiac tamponade or pericardial effusion was, however, presented in these studies. 27, 75, 76, 85 Discussion Cardiac surgery is increasingly offered to older patients with coexisting comorbidities, 86 and it is certain that the incidence of VTE after cardiac surgery will be increasing. Although VTE is an important preventable cause of morbidity and mortality in hospitalized patients, both the quality and amount of evidence to guide VTE prophylaxis after cardiac surgery were relatively sparse. With the evidence available, we confirmed that VTE prophylaxis could reduce the risk of PE and symptomatic VTE after cardiac surgery without increasing risk of bleeding and cardiac tamponade, unless the patients were systemically anticoagulated. Although some risk factors for VTE were specifically related to cardiac surgery, many important risk factors for VTE after cardiac surgery were indeed similar to risk factors for VTE in other patient populations. These results are clinically relevant and require further discussion. First, although we demonstrated that some form of VTE prophylaxis was effective in reducing PE and symptomatic VTE, we could not identify whether 1 form of VTE prophylaxis was more effective than another, nor whether 1 particular pharmacological agent was superior to the others. Recent studies showed that platelets play a significant role in the pathogenesis of VTE and antiplatelet agents can have a protective effect against the first episode of VTE in patients with hip fracture or undergoing hip arthroplasty (n=13 356) and recurrent VTE after treatment with systemic anticoagulation.
87- 91 Our results showed that aspirin appears to be effective in reducing VTE after cardiac surgery in the pediatric population (using 5 mg/kg/day) 45 or when a higher dose of aspirin is used in adults (>300 mg/day). 68 Evidence suggests that aspirin resistance is common within the first week after cardiac surgery and the standard low-dose aspirin (100 mg/ day) would not be adequate to exert its full antiplatelet effects in many patients. [11] [12] [13] Because cardiac surgical patients are also prothrombotic postsurgery (up to 30 days), 6-9 use of low-dose antiplatelet agents alone would not be sufficient in preventing VTE during this high-risk period if the patients have multiple risk factors for VTE (Table 3) . We noted that fatal PE after cardiac surgery still occurred within the last decade despite advances in cardiac surgical care, including routine use of low-dose aspirin post-CABG. 23, 26, 71, 73, 77 Fatal PE accounted for approximately 11% to 20% of all unexplained deaths after cardiac surgery, with at least 50% not diagnosed before death. 57, 58 Median incidence of fatal PE (0.3%) reported in this review was consistent with the data from these 2 postmortem reports if the overall mortality after cardiac surgery was approximately 3%, and this may, in part, explain why omission of early VTE prophylaxis is associated with an increased mortality in the critically ill. 92 Initiating UFH or LMWH, which offers additional VTE protection above intermittent pneumatic lower-limb compression, 93, 94 should Figure 6 . Funnel plot showing a lack of publication bias, using all forms of venous thromboembolic events as an outcome. RR indicates relative risk.
be seriously considered for all cardiac surgical patients as soon as possible, or on postoperative day 1, if the patients have no active bleeding, especially for those with multiple risk factors for VTE. Second, we could not identify sufficient data to support the notion that use of low-dose UFH or LMWH would increase the risks of bleeding (eg, mediastinal, intracranial, or gastrointestinal hemorrhage), pericardial effusion, and cardiac tamponade. 4 Though these complications are not rare after surgery, 76, 95, 96 whether low-dose UFH or LMWH would substantially increase such risks remains scientifically unproven. In one large, retrospective cohort study, use of UFH or LMWH at 48 hours post-CABG was not associated with an increased risk of bleeding compared to no VTE prophylaxis. 19 Using different doses of enoxaparin (20 vs.
40 mg/day) for VTE prophylaxis after proximal aortic surgery also did not appear to affect incidence of pericardial effusion nor risk of cardiac tamponade requiring surgical interventions. 75 In fact, most studies reported that bleeding after cardiac surgery only occurred in the presence of systemic anticoagulation, 35, [52] [53] [54] 78 especially when patients were overanticoagulated. 53, 54 Of all the studies included in this review, only 1 study reported risk factors for bleeding after using multivariate analysis, and it showed that only concurrent use of systemic anticoagulation with an antiplatelet agent was associated with an increased risk of bleeding. 53 Nevertheless, most reported studies are underpowered to detect small increases in rare side effects; clinicians should still be mindful about the rare, but serious, effect of pericardial hematoma before initiating anticoagulants. Perhaps, a lower than usual threshold to cease the bridging UFH (subcutaneously or intravenously) or LMWH would reduce a patient's risk of bleeding and cardiac tamponade, while the patient is taking concurrent aspirin and warfarin (eg, when INR >1.5).
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The last consideration is the limitations of this systematic review. Although we have searched extensively for the evidence on risks and benefits of VTE prophylaxis after cardiac surgery, there is an obvious evidence gap, suggesting that an adequately powered RCT is needed to confirm whether initiating low-dose UFH or LMWH from postoperative day 1 after cardiac surgery would be more cost-effective than using low-or high-dose aspirin, warfarin, or intermittent lowerlimb pneumatic compression alone in reducing morbidity and mortality of VTE. Our results suggested that DVT could be more common in the leg with the great saphenous vein harvested for CABG. This finding is not surprising because the lower-limb venous system has been disrupted after the great saphenous vein is harvested. Whether this increased risk was also contributed by wound pain causing immobilization, intolerance to graduate compression stockings, or intermittent pneumatic compression remains uncertain. Finally, we noted that many studies have a relatively short followup period in detecting VTE. With those studies with an extended follow-up period beyond the acute hospital stay, 23, [44] [45] [46] 49, 59, 71 symptomatic VTE continued to occur.
Hence, future cohort studies and RCTs on VTE after cardiac surgery should consider VTE events well beyond the immediate postoperative period.
In conclusion, PE and symptomatic VTE are not rare after cardiac surgery and these events can be reduced with VTE prophylaxis. Data on whether one form of VTE prophylaxis is superior to another are sparse. Although VTE rates appeared to be similar between patients taking high-dose aspirin (>300 mg/day for adults and 5 mg/kg/day for children) and warfarin, low-dose aspirin (100 mg/day) used to keep the bypass graft patent is unlikely to be adequate in preventing VTE post-CABG, especially for patients with multiple risk factors for VTE. We found no evidence to support the notion that use of lowdose UFH or LMWH for VTE prophylaxis would increase risk of cardiac tamponade or bleeding after cardiac surgery. Bleeding after cardiac surgery is mainly related to systemic overanticoagulation or concurrent use of systemic anticoagulation andplatelet agents. Unless proven otherwise by adequately powered RCTs, initiating low-dose UFH or LMWH as soon as possible or on postoperative day 1 after cardiac surgery for patients who have no active bleeding is highly recommended, especially if they have multiple risk factors for VTE. 
